不同技术检测利福平耐药预测耐多药结核病的可靠性分析OA北大核心CSTPCD

Objective:To evaluate the reliability of rifampicin-resistance(RR)detected by different diagnostics as a predictor for multidrug-resistant tuberculosis(MDR-TB).Methods:A retrospective study was performed by searching the Hospital Information System of Henan Chest Hospital.A total of 130 TB patients who had performed Mass ARRAY assay for drug resistance detection from July 2021 to November 2022 were enrolled.Of these patients,their GeneXpert MTB/RIF assay(Xpert)and phenotypic drug susceptibility testing(pDST)results were collected for comparative analysis.Results:Among the 130 enrolled patients,37(28.46％)were reported as RR by Mass ARRAY,38(37.25％)of 102 patients with Xpert-positive result were categorized as RR patients,22(45.83％)of the 48 patients who underwent pDST after a positive culture were categorized as RR.Among patients with RR detected in Mass ARRAY,the proportion of MDR diagnosed by Mass ARRAY and pDST was 83.78％(31/37)and 90.48％(19/21),respectively.Among RR patients detected by Xpert,the proportion of MDR diagnosed by MassARRAY and pDST was 73.68％(28/38)and 76.00％(19/25),respectively.In patients with RR detected by pDST,the proportion of MDR diagnosed by MassARRAY and pDST was 90.91％(20/22)and 95.23％(20/21),respectively.Among RR patients diagnosed both by MassARRAY and Xpert,88.89％(24/27)and 88.89％(16/18)were diagnosed as MDR by MassARRAY or pDST,respectively.Among RR patients detected by any method of MassARRAY or Xpert,72.92％(35/48)and 75.00％(21/28)were reported as MDR by MassARRAY or pDST,respectively.Conclusion:The RR diagnosed by different diagnostics is a reliable indicator of MDR-TB,but the predictive reliability is related to the accuracy of RR diagnosis.